---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Phase of product development"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Phase of product development. Topics: Regulatory status: Submission planned; U.S. accelerated approval application planned if the AMPLITUDE interim analysis, with data expected in early 2027, is positive; Authorisation status in the European Union: not authorised; Pivotal AMPLITUDE trial: full enrollment completed in 2026; Interim analysis timing: company guidance from January 2025 to November 2026; 14 further topics. 18 evidence topics quoted from 17 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/phase-of-product-development"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Phase of product development

<a id="heading-2.1.1"></a>

## 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

### Regulatory status: Submission planned; U.S. accelerated approval application planned if the AMPLITUDE interim analysis, with data expected in early 2027, is positive

> “Having completed enrollment in the interim analysis (IA) cohort of the AMPLITUDE pivotal study last year, Vertex has now completed full enrollment. Vertex remains on track to conduct the pre-planned IA for potential U.S. accelerated approval after the IA cohort reaches 48 weeks of treatment and to share data from the IA in early 2027.”

Source: [Vertex Pharmaceuticals third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm)

> “We are on track to conduct the pre-planned interim analysis for potential U.S. accelerated approval once the interim analysis cohort has been treated for 48 weeks and to share data from the interim analysis in early 2027.”

Source: [Vertex Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/vrtx-20260930.htm)

> “Vertex is on track to share data from the pre-planned interim analysis (IA) of AMPLITUDE in early 2027 once the IA cohort reaches 48 weeks of treatment. If positive, the data could form the basis for potential accelerated approval in the U.S.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

> “potential to file for accelerated approval in the U.S. if 48-week interim analysis data positive”
> “If positive, the IA will serve as the basis for Vertex to seek accelerated approval of inaxaplin in the U.S.”

Source: [Vertex Pharmaceuticals press release, kidney portfolio advancements (2025)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-key-advancements-across-kidney-portfolio)

<a id="topic-2.1.1-2"></a>

### Launch

No evidence found.

<a id="topic-2.1.1-3"></a>

### Authorisation status in the European Union: not authorised

| Field | Quoted record |
| --- | --- |
| Investigational medicinal product | “VX-147 film-coated tablet” |
| Active substance | “Inaxaplin” |
| Authorisation status | “Not authorised” |
| Medicine status in the EU | “No EU-wide authorisation listed” |

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-2.1.1-4"></a>

### Pivotal AMPLITUDE trial: full enrollment completed in 2026

> “We have completed full enrollment in the AMPLITUDE pivotal clinical trial evaluating inaxaplin.”

Source: [Vertex Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/vrtx-20260930.htm)

> “Vertex has completed full enrollment in the Phase 2/3 AMPLITUDE study of inaxaplin in people with severe proteinuria and no other kidney disease-causing comorbidities.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-2.1.1-5"></a>

### Interim analysis timing: company guidance from January 2025 to November 2026

> “Vertex expects to complete enrollment in the interim analysis cohort in 2025 for potential accelerated approval in the U.S., once this cohort reaches 48 weeks of treatment.”

Source: [Vertex Pharmaceuticals press release, pipeline and business updates (2025)](https://news.vrtx.com/news-releases/news-release-details/vertex-provides-pipeline-and-business-updates-advance-upcoming-0)

> “In September, Vertex completed enrollment in the interim analysis cohort of the AMPLITUDE Phase 2/3 trial of inaxaplin in patients with primary AMKD and will conduct the pre-planned interim analysis once this cohort reaches 48 weeks of treatment. Vertex expects to share data from the interim analysis in late 2026 or early 2027.”

Source: [Vertex Pharmaceuticals press release, pipeline and business updates (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-provides-pipeline-and-business-updates-advance-upcoming-1)

> “Vertex remains on track to conduct the pre-planned IA for potential U.S. accelerated approval after the IA cohort reaches 48 weeks of treatment and to share data from the IA in early 2027.”

Source: [Vertex Pharmaceuticals third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm)

<a id="topic-2.1.1-6"></a>

### Interim analysis endpoints: company wording from March 2022 to September 2025

> “The study is also designed to have a pre-planned interim analysis at Week 48 evaluating eGFR slope in VX-147 versus placebo, supported by a percent change from baseline in proteinuria. If positive, the interim analysis may serve as the basis for Vertex to seek accelerated approval of VX-147 in the U.S. for patients with AMKD.”

Source: [Vertex Pharmaceuticals press release, pivotal development (2022)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-vx-147-pivotal-clinical-development-people-apol1)

> “The study is also designed to have a pre-planned interim analysis at Week 48 evaluating eGFR slope, supported by a percent change from baseline in UPCR in the inaxaplin arm versus placebo.”

Source: [Vertex Pharmaceuticals press release, Breakthrough Therapy and PRIME designations (2022)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-inaxaplin-vx-147-granted-breakthrough-therapy)

> “The trial has a pre-planned interim analysis at Week 48 evaluating proteinuria, as measured by the percent change from baseline in UPCR, and eGFR slope.”

Source: [Falk et al. (2022)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20223311s1181c~design-of-a-phase-23-adaptive-trial-evaluating-inaxaplin-in)

> “The study is also designed to have a pre-planned interim analysis at Week 48 evaluating eGFR slope, supported by a percent change from baseline in proteinuria in the inaxaplin arm versus placebo. If positive, the interim analysis may serve as the basis for Vertex to seek accelerated approval of inaxaplin in the U.S. for patients with AMKD.”

Source: [Vertex Pharmaceuticals press release, phase 3 advancement (2024)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-inaxaplin-vx-147-phase-3-portion-adaptive-phase)

> “The AMPLITUDE study is designed with an interim analysis at Week 48 in a pre-specified number of patients to assess percent change from baseline in proteinuria and eGFR slope in the inaxaplin arm versus placebo.”

Source: [Vertex Pharmaceuticals press release, kidney portfolio advancements (2025)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-key-advancements-across-kidney-portfolio)

<a id="topic-2.1.1-7"></a>

### Interim analysis endpoints: registered primary endpoints

> “Part A: Percent change in UPCR evaluated from baseline at Week 48 (assessed at the IA) • eGFR slope (with ≥48 weeks of eGFR data assessed at the IA and at least 2 years of eGFR data assessed at the final analysis)”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

> “Part A: Percent Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) at Week 48 (Assessed at the Week 48 Interim Analysis)”

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="topic-2.1.1-8"></a>

### Interim analysis endpoint agreed with the FDA: eGFR slope

> “We are very pleased to have concluded our discussions with the FDA, enabling us to initiate the pivotal development program evaluating VX-147 in the broad patient population with AMKD and to have a clear path forward for potential accelerated approval in the U.S.”

Source: [Vertex Pharmaceuticals press release, pivotal development (2022)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-vx-147-pivotal-clinical-development-people-apol1)

> “A win would be a statistically significant result on the GFR slope. And I say that because, of course, we are going to measure proteinuria and GFR. But our agreement with the FDA, on what would be acceptable for accelerated approval is GFR.”
> “And at the same time, the FDA and our agreement is indeed with GFR. So, given that, we are focused on GFR.”

Source: [Vertex Pharmaceuticals earnings call transcript (2026)](https://www.webull.com/news/15858478693325824)

<a id="topic-2.1.1-9"></a>

### Breakthrough Therapy designation for APOL1-mediated FSGS, June 2022

> “Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has granted inaxaplin (VX-147) Breakthrough Therapy Designation for APOL1-mediated focal segmental glomerulosclerosis (FSGS) and the European Medicines Agency (EMA) has granted inaxaplin Priority Medicines (PRIME) designation for APOL1-mediated chronic kidney disease (AMKD).”
> “The Breakthrough Therapy Designation was granted based on the Phase 2 clinical study of inaxaplin in patients with APOL1-mediated FSGS, a form of AMKD.”

Source: [Vertex Pharmaceuticals press release, Breakthrough Therapy and PRIME designations (2022)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-inaxaplin-vx-147-granted-breakthrough-therapy)

> “The FDA has granted Breakthrough Therapy designation to inaxaplin, and the European Medicines Agency (EMA) has granted PRIME designation.”

Source: [Vertex Pharmaceuticals third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm)

<a id="topic-2.1.1-10"></a>

### PRIME designation for AMKD, May 2022

> “PRIME designation was granted based on clinical proof-of-concept data from Vertex’s Phase 2 study of inaxaplin in APOL1-mediated FSGS. Inaxaplin is only the second nephrology product to be granted PRIME designation.”

Source: [Vertex Pharmaceuticals press release, Breakthrough Therapy and PRIME designations (2022)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-inaxaplin-vx-147-granted-breakthrough-therapy)

> “In the PRIME scheme (EMA priority medicines) since 19 May 2022”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-2.1.1-11"></a>

### Rare Pediatric Disease designation for APOL1-mediated FSGS

> “The U.S. Food and Drug Administration (FDA) has granted inaxaplin Rare Pediatric Disease Designation (RPD) and Breakthrough Therapy Designation (BTD) for APOL1-mediated focal segmental glomerulosclerosis (FSGS). The European Medicines Agency (EMA) has also granted inaxaplin Priority Medicines (PRIME) and Orphan Drug designations for AMKD.”

Source: [Vertex Pharmaceuticals press release, phase 3 advancement (2024)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-inaxaplin-vx-147-phase-3-portion-adaptive-phase)

<a id="topic-2.1.1-12"></a>

### EU orphan designation EU/3/22/2697, October 2022

> “This medicine was designated as an orphan medicine for the treatment of apolipoprotein L1-mediated kidney disease in the European Union on 11 October 2022.”

Source: [EMA orphan designation EU/3/22/2697 (2022)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2697)

| Field | Quoted record |
| --- | --- |
| Active substance | “Inaxaplin” |
| Intended use | “Treatment of apolipoprotein L1-mediated kidney disease” |
| Orphan designation status | “Positive” |
| EU designation number | “EU/3/22/2697” |
| Date of designation | “11/10/2022” |
| Sponsor | “Vertex Pharmaceuticals (Ireland) Limited” |

Source: [EMA orphan designation EU/3/22/2697 (2022)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2697)

<a id="topic-2.1.1-13"></a>

### EU paediatric investigation plan EMEA-003368-PIP01-22, agreed October 2023

| Field | Quoted record |
| --- | --- |
| Active substance | “Inaxaplin” |
| Decision number | “P/0430/2023” |
| PIP number | “EMEA-003368-PIP01-22” |
| Pharmaceutical form | “Film-coated tablet” |
| Condition | “Treatment of apolipoprotein L1 (APOL1)-mediated kidney disease” |
| Route of administration | “Oral use” |
| Decision date | “27/10/2023” |

Source: [EMA paediatric investigation plan EMEA-003368-PIP01-22 (2023)](https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003368-pip01-22)

> “EMA decision of 27 October 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for inaxaplin”

Source: [EMA paediatric investigation plan EMEA-003368-PIP01-22 (2023)](https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003368-pip01-22)

<a id="topic-2.1.1-14"></a>

### FDA orphan drug and Fast Track designations

No evidence found.

<a id="topic-2.1.1-15"></a>

### First-in-human study, June 2019 to January 2020

> “The first-in-human study of inaxaplin (Study VX18-147-001 or Study 1) evaluated single ascending doses of 7.5 mg up to 50 mg and multiple ascending doses of 15 mg once daily, 15 mg twice daily, or 45 mg once daily in healthy participants.”
> “Study 1 was conducted at two sites in the United States (Madison, WI and Dallas, TX) between June 2019 and January 2020.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-2.1.1-16"></a>

### Phase 2a proof-of-concept results, December 2021

> “Based on these results, Vertex plans to advance VX-147 into pivotal development in APOL1-mediated kidney disease, including FSGS, in Q1 2022.”

Source: [Vertex Pharmaceuticals press release, phase 2 results (2021)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2-study-vx-147-apol1)

<a id="topic-2.1.1-17"></a>

### Pivotal phase 2/3 trial initiated, March 2022

> “Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has advanced VX-147 into pivotal development for people living with proteinuric kidney disease mediated by two mutations in the APOL1 gene (AMKD), which affects approximately 100,000 people in the U.S. and Europe.”
> “The pivotal study will open for enrollment later this month.”

Source: [Vertex Pharmaceuticals press release, pivotal development (2022)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-vx-147-pivotal-clinical-development-people-apol1)

<a id="topic-2.1.1-18"></a>

### Phase 3 portion and adolescent expansion, April 2024

> “Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that inaxaplin (VX-147) has advanced into the Phase 3 portion of the global Phase 2/3 pivotal clinical trial in APOL1-mediated kidney disease (AMKD), where a 45 mg once daily oral dose will be compared to placebo, on top of standard of care.”
> “In addition, the trial has been expanded to include adolescents with AMKD ages 10 to 17 years.”

Source: [Vertex Pharmaceuticals press release, phase 3 advancement (2024)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-inaxaplin-vx-147-phase-3-portion-adaptive-phase)

<a id="topic-2.1.1-19"></a>

### Interim analysis cohort enrolled, September 2025

> “Vertex also announced today enrollment completion of the IA cohort of AMPLITUDE, a global Phase 2/3 clinical trial designed to assess the impact of inaxaplin on kidney function and proteinuria for people living with AMKD.”

Source: [Vertex Pharmaceuticals press release, kidney portfolio advancements (2025)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-key-advancements-across-kidney-portfolio)

<a id="topic-2.1.1-20"></a>

### Phase 2b AMPLIFIED results, September 2026

> “Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease (AMKD) and modest proteinuria and in people with AMKD and type 2 diabetes.”
> “We look forward to discussing the AMPLIFIED results with regulators in the context of the AMPLITUDE pivotal study.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
